Clinical Trials Browser

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT01362803 2026-06-01

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

Phase 1/2 Active not recruiting

99 enrolled 1 FDA

CNS

Neurofibromatosis 1, Pain, Neurofibroma, Plexiform

NCT05363267 2026-06-01

NF-1, Nutraceutical Intervention

Phase 1 Active not recruiting

23 enrolled

CNS

Neurofibromatosis 1

NCT06188741 2026-05-29

NF114

Phase 2 Recruiting

200 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03190915 2026-05-27

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Phase 2 Active not recruiting

10 enrolled 11 charts

CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT03433183 2026-05-27

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Phase 2 Completed

21 enrolled 12 charts

CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

NCT05101148 2026-05-20

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Phase 1 Active not recruiting

24 enrolled

CNS

Neurofibromatosis 1

NCT06541847 2026-05-19

INSPIRE-NF1

Phase 2 Recruiting

25 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT04590235 2026-05-14

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Phase 1 Active not recruiting

32 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT01089101 2026-05-13

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Phase 1/2 Active not recruiting

217 enrolled

CNS

Astrocytoma, Neurofibromatosis 1

NCT07102394 2026-05-08

Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

Phase 1 Recruiting

10 enrolled

CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses

NCT04763109 2026-05-07

Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence

Phase NA Recruiting

15 enrolled

CNS

Neurofibromatosis 1

NCT03962543 2026-05-06

ReNeu

Phase 2 Active not recruiting

114 enrolled 25 charts 1 FDA

CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT03363217 2026-04-24

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Phase 2 Active not recruiting

114 enrolled

CNS

Brain Neoplasms, Glioma, Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06300502 2026-04-22

Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)

Phase 1 Enrolling by invitation

15 enrolled

CNS

Neurofibroma, Neurofibromatosis 1

NCT04481035 2026-04-21

NF1NAC

Phase 2 Completed

5 enrolled 10 charts

CNS

Neurofibromatosis 1

NCT05849662 2026-04-15

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Phase 1/2 Recruiting

58 enrolled

CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT03871257 2026-04-13

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Phase 3 Active not recruiting

165 enrolled

CNS

Neurofibromatosis 1

NCT07521657 2026-04-13

NF118

Phase 2 Not yet recruiting

55 enrolled

CNS

Glioblastoma, Glioma, Neurofibromatosis 1

NCT05735717 2026-04-06

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Phase 2 Recruiting

70 enrolled

CNSClassical hematologyLymphoidOther hematologic neoplasm

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT04924608 2026-03-23

KOMET

Phase 3 Active not recruiting

145 enrolled 17 charts 1 FDA

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

Clinical Trials

DoDNAC

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

PF-07284892 in Participants With Advanced Solid Tumors

Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs)

Pediatric Long-Term Follow-up and Rollover Study

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

NF-1, Nutraceutical Intervention

NF114

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

INSPIRE-NF1

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence

ReNeu

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)

NF1NAC

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

NF118

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

KOMET